Log In
BCIQ
Print this Print this
 

Farxiga, Forxiga, dapagliflozin

Also known as: formerly BMS-512148

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$4,100.0M

$2,700.0M

$1,400.0M


 Deals Details
Get a free BioCentury trial today